Morningstar

First-in-Human Use of CereVasc® eShunt® System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical Outcomes

BOSTON, March 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel minimally invasive treatments for neurological diseases, today announced the publication ...
Hosted on MSN

Neuralink human trials: What the brain implant tests involve?

Neuralink’s first brain implant in a human patient took place in January 2024, but the details of what the company’s clinical trial actually requires of participants, regulators, and the company ...
Business Insider

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to ...
Morningstar

VS3 Medical Announces First Patients Enrolled in First-in-Human Study of Novel Neurovascular Implant to Address Symptomatic Venous Sinus Stenosis

VS3 Medical Announces First Patients Enrolled in First-in-Human Study of Novel Neurovascular Implant to Address Symptomatic Venous Sinus Stenosis VS3 Medical, Inc., a private company developing novel ...
Seeking Alpha

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple ...

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
UUHC Health Feed

First Three Patients Treated with Novel Theranostics Drug in First-in-Human Clinical Trial

The first three patients in the world have been treated in a Phase 1 clinical trial of RYZ401. RYZ401 is a novel radiopharmaceutical that specifically targets somatostatin receptors on neuroendocrine ...
The Manila Times

Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis ...
Business Wire

INBRAIN Neuroelectronics Completes Enrolment of World’s First-in-Human Study of Graphene Neural Interfaces for Brain Decoding & Mapping

BARCELONA, Spain--(BUSINESS WIRE)--INBRAIN Neuroelectronics, a neurotechnology company developing graphene-based brain-computer interface therapeutics (BCI-Tx), today announced completion of patient ...